Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Sulfasalazine

Asulfadine, azulfidine, salazopyrine. Drug-induced involvement in inflammatory bowel disease is against the specific respiratory manifestations of UC and CD (PMID: 22958334; 24525506)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)
I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g

Pulmonary fibrosis
I.n

ILD with a granulomatous component

XLI - Pulmonary edema - Acute lung injury - ARDS

XLI.b

Pulmonary edema, cardiogenic

XLIII - Airway involvement

XLIII.t

Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

XLV - Pleural and/or pericardial involvement

XLV.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
XLV.b

Eosinophilic pleural effusion
XLV.d

Pleural/pericardial effusion, ANA positive (DI lupus)
XLV.m

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLVI - Pulmonary vasculopathy

XLVI.d

Pulmonary vasculitis or capillaritis

XLVII - Mediastinal involvement

XLVII.a

Lymphadenopathy (intrathoracic)

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.a

DRES syndrome - DRESS-like reaction
XLIX.d

Lupus - Lupus syndrome (see also Vd)
XLIX.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
XLIX.m

Sarcoid-like granulomatosis (endo-/extrathoracic)
XLIX.u

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
XLIX.w

Multiple organ dysfunction/failure (MODS/MOF)

L - Miscellaneous

L.b

Chest pain (acute or subacute), lone or prominent
L.c

Pleuritic chest pain

LI - Cardiovascular involvement / toxicity

LI.c

Pericardial effusion (w/wo tamponade)
LI.d

Myocarditis (can be fulminant)
LI.i

Eosinophilic myocarditis

LIII - Hemoglobinopathies - Abnormal hemoglobin states (acquired)

LIII.a

Methemoglobinemia

LVII - Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a

BAL: An excess proportion of lymphocytes
LVII.c

BAL: An excess proportion of eosinophils

LVIII - Pathology

LVIII.d

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
LVIII.f

Path: ILD with a granulomatous component (see also Im)
LVIII.k

Path: Desquamative interstitial pneumonia (DIP-pattern)
LVIII.o

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
LVIII.ay

Path: Pulmonary vasculitis other than capillaritis

LIX - Infections & related conditions

LIX.v

Hypogammaglobulinemia - Antibody deficiency